Abstract
Introduction: Breast cancer (BC) is the most common cancer among women worldwide. With increasing survival rates, focus has expanded to long-term adverse effects of adjuvant chemotherapy and/or aromatase inhibitors. Weight gain during chemotherapy has been well documented, but the underlying mechanisms remain unclear. A change in glucose and insulin metabolism is a possible consequence. Methods: We searched PubMed on the 4th of May 2018, and found eight articles that compared measurements of glucose and insulin before and after chemotherapy and/or aromatase inhibitors in woman with BC. Results: A general trend of increased glucose and insulin is seen and likely to be caused by weight gain and/or changes in body composition as a consequence of adjuvant treatment of BC. Discussion: Due to methodological limitations including short follow-up times and small sample sizes, further studies are required to better describe metabolic consequences of adjuvant chemotherapy and/or aromatase inhibitors. Future studies could help identify patients in high-risk of developing cardiometabolic disease after BC treatment.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Cancer Medicine |
| Vol/bind | 8 |
| Udgave nummer | 1 |
| Sider (fra-til) | 238-245 |
| Antal sider | 8 |
| ISSN | 2045-7634 |
| DOI | |
| Status | Udgivet - 2019 |
FN’s Verdensmål
Dette resultat bidrager til følgende verdensmål
